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Adjuvant intravaginal brachytherapy (IVBT) is an evidenced-
based strategy that signiﬁcantly reduces the long-term rate of post-
hysterectomy vaginal mucosal relapse in women with intermediate
and high-risk endometrial cancer (EC) (Nout et al., 2010). Due to
the physical properties of brachytherapy, optimal IVBT dose delivery
is dependent on close conformance of the vaginal applicator with
the mucosal target tissue. Internationally (Nout et al., 2010; Small et
al., 2005) the standard IVBT applicator is a multi-diameter rigid round-
topped segmented or solid plastic cylinder with a central metal tandem
catheter. A recent study however, has questioned the anatomic suitabil-
ity of the rigid cylinder system in all post-hysterectomy EC patients and
suggested that IVBT be customized to the ﬁnal vaginal vault topography
(Miller et al., 2010).Weused this approach in anunusual case of bilateral
EC in a patient with a congenital Mullerian tract anomaly (uterus
didelphys; UD).
Case history
In May 2010, a 78-year-old nulliparous woman (BMI 36 kg.m−2)
with known UD and previous vaginal septoplasty was investigated
for post-menopausal bleeding. Speculum examination revealed bilat-
eral cervices with an intervening partial septum within the proximal
vagina. Abdominal ultrasound showed complete reproductive tract
duplication without renal dysgenesis. Fractional curettage conﬁrmedCancer Centre, Royal North Shore Hospital,
266833.
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differentiated (G1) endometrioid adenocarcinoma in each hemi-
uterus and subsequent surgical staging (Fig. 1) demonstrated deeply
inﬁltrating Grade 1 endometrioid adenocarcinoma of the right hemi-
uterus (12 mm of 20 mm thick myometrium) with lymph-vascular
space invasion (FIGO 2008 Stage IB). No residual EC was found within
the hypoplastic left uterus (ﬁnal FIGO Stage IA without invasion).
Lymph node sampling was not considered due to the low histological
grade at curettage. Adjuvant IVBT was recommended based on her
high intermediate-risk status (i.e. age >70 years, deepmyometrial in-
ﬁltration and lymph-vascular space invasion) (Nout et al., 2010; Kunos
et al., 2011).Fig. 1. Uterus didelphys (UD): In vivo (top) and ex vivo (bottom). Note larger right
hemi-uterus (*), normal paired fallopian tube and ovary, and presence of the recto-vesical
ligament between the hemi-uteri. The latter is a pathognomonic ﬁnding in UD.
icense.
Fig. 2. Final IVBTmould constructed from vaginal alginate impression. Note noncylindrical
conﬁguration, asymmetric proximal expansion, andmulti-cathererHDRB loading capacity.
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gross disturbance of proximal vaginal topographywith deep involution
of the central vault due to duplicated vaginas and attempted resection
of the septal remnant. At the time of brachytherapy assessment,
standard “best-ﬁt” cylinder IVBT was seen to be anatomically non-
conformal with the vaginal mucosa on pelvic CT scan. A vaginal mould
was thus constructed using the Institut Gustave Roussey “moulage”
technique (Albano et al., 2008) (Fig. 2). Brieﬂy, the moulage method
uses a liquid alginate paste to capture a precise impression of surface
topography of the vaginal vault and shaft. With the patient in the dorsal
lithotomy position, alginate paste was injected to ﬁll the vagina under
light pressure. The paste solidiﬁes within minutes forming an alginate
“caste” which was extracted using a modiﬁcation of the Gustave
Roussey gauze strip system (we used corrugated plastic tape) and
converted to a personalized acrylic mould into which multiple brachy-
therapy source catheters were positioned and ﬁxated with wax. In our
patient excellent mould-to-mucosa conformance was ﬁnally achieved
using this anatomical customizing system. Before treatment in vivo
CT modelling of her vaginal mucosal surface dose (45-mm length)
with the Oncentra Brachytherapy Planning System (v3.3; Nucletron
Corporation, Veenendaal, Netherlands) determined an optimal multi-Fig. 3. Screen shot from Oncentra brachytherapy planning system (BPS; Nucletron B.V., Veen
der and rectum (with contrast). Excellent mould-to-mucosa conformity in trans-axial (top)
D2cc per fraction (279 cGy) and bladder D2cc (400 cGy.)catheter source loadingpattern (Fig. 3). Rectal, bladder, and vaginalmu-
cosal volumetric exposureswere recorded. Two insertions in 8 days de-
livered a vaginal surface dose of 3000 cGy in 6 fractions.
At 20 months post-IVBT, the patient remains disease-free with
normal vaginal cytology and no vaginal, rectal, or bladder toxicity.
Discussion
Uterus didelphys (UD) exists within a spectrum of congenital
anomalies in which there is complete non-fusion of the Mullerian
tracts resulting in parallel duplication of the female reproductive or-
gans (uterine corpus, cervix, and vagina) sometimes with renal dys-
genesis. The incidence of UD is 0.1% to 0.5% (Grimbizis and Campo,
2010) and is usually asymptomatic until fertility or obstetric issues
occur. Longitudinal studies have shown that a didelphic uterus per
se does not however predispose to malignancy (Heinonen, 2009) .A
total of 9 cases of unilateral EC have been reported in the English lit-
erature from 1962 to 2009 (Heinonen, 2009; Dane et al., 2009).
Synchronous endometrial cancers (EC) within both hemi-uteri are
exceedingly rare having been described in only 3 previous case reports.
However, in contrast to our case, all of the latter women were pre-
menopausal and only one had high-risk EC (Fanfani et al., 2006;
Kunos et al., 2011; Bhalla et al., 2005) which required adjuvant therapy.
This patient underwent exploratory laparotomy and had resection
of her smaller hemi-uterus and ipsilateral adnexa (tubo-ovarian
metastases) before proceeding to neo-adjuvant brachytherapy. The
removal of one hemi-uterus allowed conventional intra-uterine
tandem and vaginal colpostat low dose-rate brachytherapy. This to-
gether with supplemental external radiation provided good dosimet-
ric coverage of the vagina without the compromise imposed by her
original anatomy (Fanfani et al., 2006).
The current didelphic patient with synchronous bilateral EC is the
ﬁrst in which the ﬁdelity of adjuvant intra-vaginal brachytherapy had
been prospectively questioned and for whom a customized multi-
channel vaginal mould was successfully utilised. Our ability to con-
struct and dosimetrically model to a wide range of vaginal topogra-
phies using the moulage technique has prompted a “ﬁrst-fraction”
CT simulation protocol in all EC patients requiring adjuvant high
dose-rate brachytherapy at our institution. Quality management of
this clinical pathway with pelvic CT is inexpensive (approximatelyendaal, Netherlands). Note vaginal mould in central pelvis between catheterized blad-
, coronal (bottom) and sagittal (right) planes. DVH depicting CTV D90 (500 cGy), rectal
123L. Morris et al. / Gynecologic Oncology Reports 2 (2012) 121–123US dollar 200 per case). From this experience (unpublished) we have
found signiﬁcant post-hysterectomy vaginal cylinder to mucosa non-
conformance in over 30% of women subject to pelvic CT before their ini-
tial vaginal brachytherapy fraction. It is posited that this relatively high
proportion is associatedwith the increasing use of laparoscopic surgical
techniques to close the vagina and was not a factor in our current pa-
tient with challenges imposed by her congenital anomaly and bilateral
hemi-uterine cancers.Conﬂict of interest statement
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